Status:
UNKNOWN
Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis
Lead Sponsor:
Azienda Ospedaliera Universitaria Policlinico
Conditions:
Deep Vein Thrombosis
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The duration of anticoagulant treatment in cancer patients with Deep Vein Thrombosis (DVT) of the lower limbs is still uncertain. The present study addresses the possible role of the Residual Vein Thr...
Detailed Description
BACKGROUND. Currently there is no consensus on the optimal duration of antithrombotic therapy in cancer patients experiencing a first episode of deep vein thrombosis (DVT) of lower limbs. Recent guide...
Eligibility Criteria
Inclusion
- Cancer patients with a first episode of symptomatic proximal DVT of the lower limbs
- No signs of unstable pulmonary embolism
Exclusion
- Indication to antithrombotic therapy/OAT for \> 6 months (i.e. valvular prothesis, atrial fibrillation etc.)
- Previous DVT/PE
- Hypersensitivity to contrast media
- Pregnancy
- Life expectancy \< 1 year
- Patients who are unable to fulfill study requirements as for repeated clinical controls
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2011
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00450645
Start Date
March 1 2005
End Date
March 1 2011
Last Update
March 4 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology and Haemostasi/Thrombosis Unit, University of Palermo
Palermo, Italy, 90127